- $1.59m
- -$3.49m
- $9.44m
Curis Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Curis Inc - On June 27, 2022, William Steinkrauss Notified Curis Inc Of His Intention To Resign From His Role As CFO
Brief: Curis Announces Encouraging Emavusertib Data At 2022 American Society Of Clinical Oncology Annual Meeting (ASCO)
Brief: Curis Reports First Quarter 2022 Financial Results And Business Update
Curis Inc reports results for the quarter ended in March - Earnings Summary
Curis Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Curis, Sonos, Accolade, Shopify, Hoth Therapeutics
Curis down after FDA places lymphoma drug trial on partial clinical hold
U.S. STOCKS ON THE MOVE-Curis Inc, Nvidia Corp, Veru Inc
Brief: Curis Announces FDA Partial Clinical Hold For Takeaim Lymphoma Study Of Emavusertib (CA-4948)
Curis down after FDA places lymphoma drug trial on partial clinical hold
Raymond James downgrades Curis over FDA partial clinical hold
U.S. RESEARCH ROUNDUP- Brunswick, Ezcorp, Twitter
U.S. STOCKS ON THE MOVE-SunPower, Snow Lake, Sea Ltd
U.S. STOCKS ON THE MOVE-Chinese ADRs, Star Equity, Starbucks
U.S. STOCKS ON THE MOVE-Social media apps, Curis, Gores Guggenheim
Curis drops after FDA partial clinical hold on blood disorder therapy trial
Brief: Curis Announces FDA Partial Clinical Hold For Takeaim Leukemia Study Of Emavusertib
Curis Inc reports results for the quarter ended in December - Earnings Summary